# US 6,727,259 B2 · Remedial agent for neural degeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,259 B2
- Document ID: US6727259B2
- Status: Granted
- Kind: B2
- Application number: 09/486,823
- Filed: 2000-03-03
- Published: 2003-08-21
- Granted: 2004-04-27
- Earliest claimed: 1997-09-05
- Assignees: Kyowa Hakko Kogyo Co., Ltd.
- Inventors: Junichi Shimada; Masako Kurokawa; Ken Ikeda; Fumio Suzuki; Yoshihisa Kuwana
- Web page: https://patentgrep.com/patent/US6727259B2

## CPC

- A61K 31/52: Purines, e.g. adenine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 473/06: with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to a therapeutic agent for neurodegenerative disorders, comprising a xanthine derivative represented by formula (I): or a pharmaceutically acceptable salt thereof as an active ingredient wherein X1, X2, R1, R2, R3 and R4 are herein defined.

## Claims

### Claim 1

A method of inhibiting neurodegeneration except Parkinson's disease, which comprises administering an effective dose of a xanthine derivative represented by formula (I):
or a pharmaceutically acceptable salt thereof.

### Claim 2

A method of treating neurodegenerative disorders except for Parkinson's disease, which comprises administering an effective dose of a xanthine derivative represented by formula (i):
or a pharmaceutically acceptable salt thereof.

### Claim 3

A method of treating Alzheimer's disease, which comprises administering an effective dose of the xanthine derivative represented by formula (I):
or a pharmaceutically acceptable salt thereof.
